Brain cancer hope: new drug cocktail targets rare lymphoma

NCT ID NCT04446962

Ongoing Disease control Sponsor: Institut Curie Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding lenalidomide or ibrutinib to standard chemotherapy (R-MPV) can improve outcomes for adults aged 18-65 with newly diagnosed primary central nervous system lymphoma. The trial has two parts: first, finding the safest dose, then randomly assigning patients to one of the two drug combinations. The goal is to see if more patients achieve complete remission after four cycles of treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: lenalidomide (Revlimid) and ibrutinib (Imbruvica)
What this could lead to: If successful, this could improve the chance of complete remission for people with a rare brain lymphoma, potentially leading to a more effective first treatment.
What could go wrong: This is an early-phase trial (phase 1b/2) with a small number of participants, so results may not apply broadly. The drugs can cause serious side effects like infections or blood clots.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CENTRAL NERVOUS SYSTEM NEOPLASMS, PRIMARY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

central nervous system cancer central nervous system neoplasm diffuse large B-cell lymphoma lymphoma Neurologic Manifestations primary central nervous system lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CENTRAL NERVOUS SYSTEM NEOPLASMS, PRIMARY LYMPHOMA, LARGE B-CELL, DIFFUSE

Contacts and locations

Locations

CH Colmar

Colmar, France
CH côte Basque

Bayonne, 64100, France
CHRU Lille

Lille, 69000, France
CHU Amiens

Amiens, France
CHU Angers

Angers, France
CHU Besançon

Besançon, France
CHU Caen

Caen, France
CHU Clermont-Ferrand

Clermont-Ferrand, France
CHU Créteil

Créteil, France
CHU Dijon

Dijon, France
CHU Grenoble

Grenoble, France
CHU La Timone Marseille

Marseille, France
CHU Limoges

Limoges, France
CHU Lyon

Lyon, France
CHU Nancy

Nancy, France
CHU Nantes

Nantes, France
CHU Nîmes - Carémeau

Nîmes, 30029, France
CHU Pitié-Salpêtrière

Paris, 75013, France
CHU Poitiers

Poitiers, France
CHU Rennes

Rennes, 35000, France
CHU Strasbourg-Hôpital Hautepierre

Strasbourg, 67098, France
CHU Tours

Tours, France
Centre Henri Becquerel

Rouen, 76000, France
Centre Lacassagne

Nice, France
Hôpital Cochin

Paris, 75006, France
IUCT -Oncopole

Toulouse, France
Institut Bergonié

Bordeaux, France
Institut Curie

Paris, 75005, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.